Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anil Abraham

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Current Oncology (Toronto, Ont.)|April 27, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Aalok Kumar, Katarzyna J Jerzak, Karen A Gelmon, et al.
JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled TrialTimothy A Yap, Aditya Bardia, Michael Dvorkin, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic SettingMita Manna, Karen A Gelmon, Jean-François Boileau, et al.
BMJ Open|September 19, 2019
Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trialMarnie Newell, John R Mackey, Gilbert Bigras, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025Katarzyna J Jerzak, Aalok Kumar, Jean-François Boileau, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025Christine Simmons, Omar F Khan, Christine Brezden-Masley, et al.
The Lancet. Oncology|November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 27, 2019
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker AnalysesTaofeek K Owonikoko, Huifeng Niu, Kristiaan Nackaerts, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Current Oncology (Toronto, Ont.)|April 27, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Aalok Kumar, Katarzyna J Jerzak, Karen A Gelmon, et al.
JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled TrialTimothy A Yap, Aditya Bardia, Michael Dvorkin, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic SettingMita Manna, Karen A Gelmon, Jean-François Boileau, et al.
BMJ Open|September 19, 2019
Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trialMarnie Newell, John R Mackey, Gilbert Bigras, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025Katarzyna J Jerzak, Aalok Kumar, Jean-François Boileau, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025Christine Simmons, Omar F Khan, Christine Brezden-Masley, et al.
The Lancet. Oncology|November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 27, 2019
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker AnalysesTaofeek K Owonikoko, Huifeng Niu, Kristiaan Nackaerts, et al.
Pageof 6